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Abstract
Background: The European-study on Quantifying Utility of Investment in Protection from Tobacco (EQUIPT)
project aimed to study transferability of economic evidence by co-creating the Tobacco Return On Investment
(ROI) tool, previously developed in the United Kingdom, for four sample countries (Germany, Hungary, Spain and
the Netherlands). The EQUIPT tool provides policymakers and stakeholders with customized information about
the economic and wider returns on the investment in evidence-based tobacco control, including smoking cessation
interventions. A Stakeholder Interview Survey was developed to engage with the stakeholders in early phases of the
development and country adaptation of the ROI tool. The survey assessed stakeholders’ information needs, awareness
about underlying principles used in economic analyses, opinion about the importance, effectiveness and
cost-effectiveness of tobacco control interventions, and willingness to use a Health Technology Assessment
(HTA) tool such as the ROI tool.
Methods: A cross sectional study using a mixed method approach was conducted among participating
stakeholders in the sample countries and the United Kingdom. The individual questionnaire contained
open-ended questions as well as single choice and 7- or 3-point Likert-scale questions. The results corresponding
to the priority and needs assessment and to the awareness of stakeholders about underlying principles used in
economic analysis are analysed by country and stakeholder categories.
Results: Stakeholders considered it important that the decisions on the investments in tobacco control interventions
should be supported by scientific evidence, including prevalence of smoking, cost of smoking, quality of life, mortality
due to smoking, and effectiveness, cost-effectiveness and budget impact of smoking cessation interventions. The
proposed ROI tool was required to provide this granularity of information. The majority of the stakeholders were aware
of the general principles of economic analyses used in decision making contexts but they did not appear to have
in-depth knowledge about specific technical details. Generally, stakeholders’ answers showed larger variability by
country than by stakeholder category.
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Conclusions: Stakeholders across different European countries viewed the use of HTA evidence to be an important
factor in their decision-making process. Further, they considered themselves to be capable of interpreting the results
from a ROI tool and were highly motivated to use it.
Keywords: Smoking cessation, EQUIPT, Stakeholder engagement, Return on investment, Transferability of economic
evidence
Background
Tobacco smoking is one of the most serious public
health problems both in Europe and worldwide. At the
global level, the burden of disease due to tobacco smok-
ing, including second-hand smoke, in 2010 was found to
be 6.3 million deaths and 6.3% of disability-adjusted life
years [1]. WHO estimated the percentage of deaths at-
tributable to tobacco in Europe in 2004 as 25% of all
deaths in men and 7% of all deaths in women [2]. The
costs of smoking in Europe were estimated at just above
1% of the European Union Gross Domestic Product in
2000 [3].
In 2008, WHO identified six evidence-based tobacco
control measures (the MPOWER measures) [4] that are
the most effective in reducing tobacco use: (1) monitor
tobacco use and prevention policies; (2) protect people
from tobacco smoke; (3) offer help to quit tobacco use;
(4) warn people about the dangers of tobacco; (5) en-
force bans on tobacco advertising, promotion and spon-
sorship; and (6) raise taxes on tobacco. Recent research
comparing the effects of the MPOWER measures has
found an overall decrease in the prevalence of smoking
but cross-country variations in these effects [5].
There is evidence on the cost-effectiveness of smoking
cessation interventions and wider tobacco control [6, 7].
The main objective of such a health technology assess-
ment (HTA) is to improve decision making about the
adoption and diffusion of health technologies. However,
in practice, it is not clear which HTA findings impact
upon decision making [8]. As scarce resources are
invested in HTA studies, it is important to maximize
benefits from HTA activities. Koopmanschap et al. [9]
argued that HTA research as a field is too young to
understand how policymakers handle the multidimen-
sional information of HTA studies. However, insights
into what criteria (and under what conditions) decision
makers in healthcare priority settings deem important
may promote transparency of the decision-making pro-
cedure and enable researchers to collect relevant
decision-support data [9].
Research on specific tobacco control interventions
which is needed to make evidence-based decisions is dis-
proportionate across Europe. While robust research
evaluating effectiveness and cost-effectiveness of tobacco
control policies, strategies, activities and interventions
are on the rise in Western Europe, Central and Eastern
European (CEE) countries do not have enough resources
to perform effectiveness evaluation. One way to address
this disparity is to transfer already established evidence
to decision-making policies of the CEE countries. The
European-study on Quantifying Utility of Investment in
Protection from Tobacco (EQUIPT) aims to address this
important gap.
EQUIPT was developed around evidence transferabil-
ity and diffusion of innovation theory [10, 11]. The aim
of this project was to study transferability of economic
evidence by co-creating a new Tobacco Return On In-
vestment (ROI) tool, adapted from a tool previously de-
veloped in England [7, 12], for five European member
states (Germany, Hungary, Spain, the Netherlands and
the United Kingdom), and provide policymakers and
stakeholders with customized information about the eco-
nomic and wider returns that investment in evidence-
based tobacco control, including smoking cessation,
agendas can generate. This sample represents the whole
European continent, including several cultural, social and
economic habits and traditions. The choice of countries
facilitates the transferability of the ROI tool’s results to
other countries not considered in EQUIPT [13]. The ROI
tool, which is a Markov state transition model, is able to
compare the effectiveness and costs of tobacco control
strategies both within and across several European Union
countries.
To inform the co-creation of a European decision-
support tool, a stakeholder interview survey was con-
ducted. The purpose of the survey, conducted by the
sample country-specific researchers, was to engage
stakeholders in an early phase of the development and
country adaptation of the ROI tool in order to facilitate
its later use [13]. EQUIPT considered ‘stakeholder en-
gagement’ as a tool to understand the issues that are im-
portant to transfer evidence. Research that has potential
to directly feed into policymaking is often produced
without engaging stakeholders in the research process
[14]. However, the importance of stakeholder engage-
ment in research is increasingly recognised [15] and sev-
eral reviews indicate that the interaction between health
researchers and potential users in policy and managerial
roles is a key factor associated with the impact of the
research [16–19].
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In this paper, we describe the EQUIPT Stakeholder
Interview Survey with the following three aims: (1) to in-
vestigate the criteria stemming from HTA studies that
are deemed most important for reimbursement decisions
concerning tobacco control, (2) to examine whether
there are any country differences, and (3) to examine
whether there are differences among different types of
stakeholder categories.
Methods
Scope of the survey
A cross-sectional mixed method study, in which qualita-
tive and quantitative research techniques were com-
bined, was conducted among stakeholders from the five
European countries (Germany, Hungary, Spain, the
Netherlands and the United Kingdom). The question-
naire used in the stakeholder interviews was developed
by EQUIPT project partners through an intensive de-
liberation and partly based on the Integrated-Change
(I-Change) Model and other relevant constructs re-
lated to the adoption of innovations [11, 13, 20, 21].
The survey’s results, corresponding to the priority and
needs assessment and to the awareness of stakeholders
about the principles of health economic analysis, are
presented in this paper by country and stakeholder cat-
egories. Stakeholders’ views on the possible advantages
and disadvantages of using the ROI tool, internal and ex-
ternal facilitators, and barriers of the use by intenders
and non-intenders were analysed and reported in the
framework of the I-Change model by Cheung et al. [21].
The availability and the importance of the smoking ces-
sation interventions used in the sample countries will be
reported separately, elsewhere.
Development of the questionnaire
The first English version of the questionnaire was tested
and adapted further by taking into consideration the re-
sults of the pilot studies. All country-specific inter-
viewers participated in pre-interview training, in which
they acquired knowledge on interviewing methodology
(what they should pay attention to during the interview,
how to ask, how to motivate the respondents, what is
the meaning of each question, etc.). The final version of
the questionnaire was translated by native language
speakers. Translated versions were pilot tested again in
each country, and then finalized after further adapta-
tions. The interviewers were aided by a survey handbook
as well.
Questionnaire
The first part of the questionnaire assessed the stake-
holders’ awareness of basic principles underlying an eco-
nomic analysis (e.g. what incremental cost or willingness
to pay might refer to), and about the importance,
effectiveness and cost-effectiveness of smoking cessation
interventions in general (e.g. why it is important to use
effective and cost-effective interventions). Then, a video
presentation on the existing United Kingdom version of
the Tobacco ROI tool was shown, followed by questions
about the types of information required from the
EQUIPT ROI tool. Opinion about the possible advan-
tages (e.g. the tool provides up-to-date information, rele-
vant outcomes and sufficient scientific support for
decision making, etc.) and disadvantages (e.g. the tool
requires excessive data input and it is time consuming
to use, etc.) of using the ROI tool were also assessed to-
gether with potential facilitators and barriers of use (e.g.
my boss, reimbursement agencies or ministry of health
will support me in using this tool, etc.). Additionally,
self-efficacy and intention to use was assessed. Finally,
the respondent’s awareness of the availability of smoking
cessation interventions in the target country and their
importance to the respondent were asked. The main cat-
egories of interventions were pharmacological (e.g. nicotine
replacement therapy, bupropion, varinicline), behavioural
(e.g. brief advice on smoking cessation given during one
general practitioner consultation, group counselling by spe-
cially trained professionals, mobile phone-based interven-
tions, etc.), combined (combination of pharmacological
and behavioural interventions), non-conventional (e.g. acu-
puncture, herbs, homeopathy, etc.) and population-level
preventive measures (e.g. advertising restrictions/bans, re-
strictions on smoking in workplaces and public places, tax
increase, etc.) (See Additional file 1 – EQUIPT stakeholder
interview survey questionnaire).
Open-ended questions as well as single choice and
Likert-scale questions were asked where appropriate. For
example, the questions on the stakeholders’ views on
their intention to use a tool in decision making was de-
signed as a 7-point Likert-scale (1 = ‘strongly disagree’
and 7 = ‘strongly agree’).
Stakeholder categories
Five major categories of stakeholders were defined: (1)
decision makers; (2) purchasers of services/pharma
products; (3) professional service providers; (4) evidence
generators; and (5) advocates of health promotion. The
EQUIPT team members defined the five stakeholder cat-
egories and specified the roles and positions of each
stakeholder category together. The definitions for each
category and examples are shown in Table 1. Then, the
interviewers had to recruit stakeholders in their own
countries in such a way that a minimum of three stake-
holders had to be invited from each stakeholder cat-
egory. In total, 167 stakeholders were contacted, 93 of
whom were willing to participate in the survey. An
introductory mail/email was sent to the stakeholders
introducing the EQUIPT project and the Tobacco ROI
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Table 1 Types of stakeholders
Stakeholder category Role Position (examples)
Decision maker Decision maker at the level of the national
health policy
Member of the health committee of the
Parliament or high level decision maker,
officer in the Ministry of Health
Decision maker in the central level of public
health services
Chief medical officer or other high level
decision maker in the public health service
Decision maker at the regional level in the
area of health
Member of the health committee of the
regional self-government or health officer
at the regional health authority
Local decision maker in a larger city in the
area of health
Head or member of the health committee
of the local authority
Local decision maker in a small community
(village) in the area of health
Member of the self-government or officer
in the municipality office responsible for
health issues
Local decision maker in the public health
service
Director of the local office of the public
health service
Purchasers of services/pharma products Decision maker involved in coverage decision
of health services
High level decision maker at the National
Health Insurance Fund, health insurance
company depending on the health service
of the country
Decision maker involved in coverage decision
of pharmaceuticals
High level decision maker at the National
Health Insurance Fund, health insurance
company depending on the health service
of the country
Professionals/service providers Coordinator of the local health program Officer in the local health office of the
government or the municipality
Key opinion leader physician on smoking
cessation
Director of a professional organisation of
pulmonology or other relevant discipline
or a large smoking cessation service
Physician/psychologist with an overview
on smoking cessation
Person working for smoking cessation
hot line
Evidence generators (e.g. researchers)
whose work informs policy/procurement/
delivery of services
Health technology assessment (HTA)
professional involved in the reimbursement
procedure
Officer in the local HTA office
Head of the local focal point of tobacco
control
Public health expert Director of a public health professional
association or body, or relevant academic
department
Researcher in the field of the economy of
smoking
Researcher with documented publication
in the area of the economy of smoking
(burden of disease, budget impact or
cost-effectiveness of interventions, etc.)
Expert in the area of healthcare costing Researcher with documented publication
in the area of healthcare costing or an
expert working at the National Health
Insurance Fund, health insurance company
depending on the health service of the
country, who is involved in professional
work related to financing health services/
pharma products
Advocates of health promotion Leader of an NGO Director or other leader of an NGO focusing
on tobacco control
Leader of a patient organisation Leader of a patient organisation of cancer/
chronic obstructive pulmonary disease
patients
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tool. Participants accepting the invitation then received
an information sheet and a consent form for completion.
Data were handled anonymously and treated confiden-
tially as per the conditions underlying ethics approval.
Interview, data collection and analysis
The individual – face-to-face, telephone or Skype – in-
terviews with stakeholders were conducted in the five
countries (Germany, Hungary, Spain, the Netherlands
and the United Kingdom) between April and July 2014.
The interviews, with a duration of approximately 30 mi-
nutes, were audio recorded. The answers were recorded
in a pre-prepared, unified data entry Microsoft Excel file.
Double data entry was used to guarantee a high level of
data quality. After the interview, an email was sent to all
interviewees thanking them for their participation and
providing a web link where more information about the
EQUIPT project and the ROI tool could be found.
SPSS Statistics software package was used for data
analysis. At first, we calculated the minimum and max-
imum values of the variables, the mean scores and the
standard deviations for each of the questions at an
aggregated level. Then, we calculated these measures by
stakeholder category and by country. We used Kruskal–
Wallis ANOVA test to study whether the distribution of
the answers were different by country or by stakeholder
category. This analytical technique was deemed adequate
for the purpose of this study (i.e. high level comparative
account), bearing in mind that each domain covered by
the survey would be subject to separate future analyses.
Results
A total of 93 respondents agreed to participate in the
stakeholder interview survey, of whom 62% were male
and 30.1% were Dutch, 19.4% Spanish, 18.3% German,
17.2% Hungarian, and 15.1% British. The overall re-
sponse rate was 56.9% (93/167), while it was 94.1% in
Hungary, 85.0% in Germany, 60.0% in Spain, 41.8% in
the Netherlands, and 40.0% in the United Kingdom.
Most (66.67%) of the interviews were face-to-face,
whereas 32.26% were by telephone and only 1.08% were
conducted via Skype. The breakdown of the different
stakeholder categories was as follows: decision makers
31.2%, evidence generators 26.9%, professional service
providers 19.4%, advocates of health promotion 15.1%,
and purchaser of services/pharma products 7.5% [21].
Awareness of principles underlying economic analyses in
public health
The majority of the stakeholders were familiar of basic
principles such as incremental cost, cost-effectiveness
and perspectives of health economic analysis (Table 2).
The majority of the interviewees were aware that a
cheap intervention is not necessarily cost-effective, and
that an intervention with higher societal costs than the
regular care can be cost-effective. The respondents were
least familiar with ‘willingness to pay’. There was a sta-
tistically significant difference between the countries in
respondents understanding of ‘incremental costs’. The
mean score showed reasonable agreement with the cor-
rectly phrased statement in Hungary, Germany and
Spain. The Dutch and British responders, however, were
uncertain about it (Table 2). The responses to the state-
ment related to a technical detail of health economics –
e.g. inclusion of the indirect costs in analyses from
healthcare payer perspective – showed largest variability
within countries, and the country means reflected uncer-
tainty. Unsurprisingly, evidence generators were the
most familiar group in terms of awareness of economic
concepts (Table 3).
Importance, efficacy and cost-effectiveness of smoking
cessation interventions
All stakeholders across the countries strongly agreed
that mortality and societal costs of smoking were high
and thought that its epidemic was severe (Table 4).
Respondents from the Netherlands, Hungary and Germany
were uncertain about effectiveness and cost-effectiveness
of the smoking cessation interventions, while the inter-
viewees in Spain and the United Kingdom mostly agreed
with the statements that these interventions are effective
and cost-effective. The differences were statistically signifi-
cant both for effectiveness and cost-effectiveness. Although
the level of agreement varied significantly by country, the
interviewees’ general opinion was that it was unacceptable
that smoking cessation interventions are used without
knowing their efficacy and their cost-effectiveness. There
were no large differences in these answers by stakeholder
category (Table 5). Professional service providers agreed
the most with the effectiveness and cost-effectiveness of
smoking cessation interventions, and purchasers of ser-
vices agreed the most with the statement that it is un-
acceptable that we use smoking cessation interventions
without knowing their efficacy. This was the only state-
ment in this block where there was a statistically significant
difference in the distribution of the answers by stakeholder
category.
HTA information needed by decision-makers from the ROI
tool
In general, all the listed HTA information, including
prevalence of smoking, cost of smoking, quality of life,
mortality due to smoking, effectiveness of smoking
cessation interventions (such as quit and relapse rate),
cost-effectiveness data comparing the cost of smoking
cessation interventions with its health and wider benefits
and budget impact reflecting financial outcomes specif-
ically at organisational level, was considered very
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Table 2 Awareness of stakeholders about basic health economic principles; level of agreement with statements by country (scale responses: 1 = strongly disagree; 7 = strongly
agree)




Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
‘Incremental costs’ means by how much the studied intervention itself
costs more or less than the comparator intervention
28 4.79 (1.93) 10 6.60 (0.52) 13 5.62 (1.12) 16 6.25 (0.78) 14 3.71 (1.86) 81 5.25 (1.76) <10–3
When an intervention in itself is cheap, it is always cost-effective compared
to another intervention
28 1.96 (1.40) 16 1.50 (1.42) 17 1.94 (1.75) 18 2.28 (2.02) 14 1.57 (0.76) 93 1.88 (1.53) 0.35
‘Willingness to pay’ means how much a society is willing to pay for a
quality-adjusted life year
28 4.86 (1.88) 11 4.45 (2.07) 14 3.71 (1.82) 13 4.92 (1.89) 14 3.86 (1.46) 80 4.44 (1.86) 0.14
My intervention can be cost-effective compared to another intervention,
even when its societal costs are higher than the regular care
28 5.82 (1.63) 15 4.93 (2.60) 17 5.18 (1.82) 17 5.76 (1.44) 14 4.86 (1.79) 91 5.40 (1.83) 0.23
From a healthcare payer perspective indirect costs in full (such as
productivity losses) are included
















Table 3 Awareness of stakeholders about basic health economic principles; level of agreement with statements by stakeholder category (scale responses: 1 = strongly disagree;










Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
‘Incremental costs’ means by how much the studied intervention
itself costs more or less than the comparator intervention
26 4.50 (1.77) 7 5.43 (1.90) 15 5.60 (1.64) 22 5.95 (1.50) 11 5.00 (1.84) 81 5.25 (1.76) 0.027
When an intervention in itself is cheap, it is always cost-effective
compared
to another intervention
29 1.76 (1.15) 7 2.29 (2.22) 18 2.89 (2.14) 25 1.32 (0.75) 14 1.64 (1.50) 93 1.88 (1.53) 0.027
‘Willingness to pay’ means how much a society is willing to pay
for a quality-adjusted life year
26 4.19 (1.98) 7 3.86 (2.12) 15 4.87 (0.83) 22 4.64 (2.22) 10 4.40 (1.71) 80 4.44 (1.86) 0.73
My intervention can be cost-effective compared to another
intervention, even when its societal costs are higher than the
regular care
28 4.93 (1.84) 7 5.43 (2.07) 18 5.50 (1.69) 25 5.80 (1.92) 13 5.46 (1.71) 91 5.40 (1.83) 0.24
From a healthcare payer perspective indirect costs in full (such
as 7productivity losses) are included
















Table 4 Opinion about the importance, effectiveness and cost-effectiveness of smoking cessation interventions by country (scale responses: 1 = strongly disagree; 7 = strongly
agree)
Netherlands Hungary Germany Spain United Kingdom Total Kruskal–Wallis
test
Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
The smoking epidemic is not severe in my country 28 2.00 (1.39) 16 1.44 (0.89) 17 1.82 (1.13) 18 1.50 (0.86) 14 2.50 (1.65) 93 1.85 (1.251) 0.10
Most smoking cessation interventions are effective 28 3.79 (1.52) 16 2.63 (1.31) 17 2.71 (0.85) 18 4.67 (1.75) 14 4.79 (1.42) 93 3.71 (1.639) < 10–3
Most smoking cessation interventions are cost-effective 28 4.11 (1.91) 14 2.64 (1.48) 17 3.18 (1.67) 16 4.75 (1.88) 14 5.71 (1.27) 89 4.07 (1.941) < 10–3
It is important to use smoking cessation interventions
because smoking kills a lot of people
28 6.46 (0.79) 16 6.88 (0.50) 17 5.82 (1.51) 18 6.83 (0.51) 14 6.71 (0.47) 93 6.53 (0.916) 0.009
It is important to use smoking cessation interventions
because smoking costs a lot for the society
28 6.14 (1.01) 16 6.75 (0.78) 17 5.76 (1.56) 18 6.67 (0.69) 14 6.43 (0.76) 93 6.32 (1.055) 0.032
It is unacceptable that we use smoking cessation
interventions without knowing their efficacy
27 5.89 (1.05) 16 6.88 (0.34) 17 5.65 (1.62) 17 5.41 (1.54) 14 5.43 (1.22) 91 5.86 (1.304) 0.003
It is unacceptable that we use smoking cessation
interventions without knowing their cost-effectiveness
















Table 5 Opinion about the importance, effectiveness and cost-effectiveness of smoking cessation interventions by stakeholder category (scale responses: 1 = strongly disagree;
7 = strongly agree)










Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
The smoking epidemic is not severe in my country 29 1.76 (1.22) 7 2.00 (0.58) 18 1.78 (1.44) 25 2.04 (1.40) 14 1.71 (1.14) 93 1.85 (1.25) 0.42
Most smoking cessation interventions are effective 29 3.72 (1.67) 7 3.57 (1.27) 18 4.17 (1.58) 25 3.56 (1.69) 14 3.43 (1.83) 93 3.71 (1.64) 0.72
Most smoking cessation interventions are cost-effective 27 4.26 (1.95) 6 3.83 (1.47) 18 4.39 (2.06) 24 3.71 (2.14) 14 4.00 (1.71) 89 4.07 (1.94) 0.80
It is important to use smoking cessation interventions
because smoking kills a lot of people
29 6.59 (0.83) 7 6.14 (0.90) 18 6.50 (1.34) 25 6.60 (0.76) 14 6.50 (0.76) 93 6.53 (0.92) 0.42
It is important to use smoking cessation interventions
because smoking costs a lot for society
29 6.62 (0.78) 7 5.57 (1.27) 18 6.28 (1.27) 25 6.28 (0.98) 14 6.21 (1.19) 93 6.32 (1.06) 0.15
It is unacceptable that we use smoking cessation
interventions without knowing their efficacy
28 5.75 (1.14) 7 6.71 (0.49) 18 5.33 (1.68) 25 6.24 (0.88) 13 5.62 (1.71) 91 5.86 (1.30) 0.13
It is unacceptable that we use smoking cessation
interventions without knowing their cost-effectiveness
















important and the stakeholders wanted the ROI tool to
provide all of this information (Table 6). Information on
the cost-effectiveness of smoking cessation interventions
was found to be the most important health technology
assessment (HTA) information in most countries (except
in Hungary and Germany, where the costs of smoking
had the largest mean score; Table 6). In Hungary, the
burden of disease due to smoking measures (prevalence,
costs and mortality of smoking, effect on quality of life)
had higher mean scores than in any of the other partici-
pating countries. Nevertheless, health economic mea-
sures were not undervalued in Hungary compared to the
other countries. In countries where cost-effectiveness
was considered to be the most important of the HTA
data to be included, it was followed by the cost of smok-
ing in the United Kingdom, effectiveness of smoking
cessation interventions in the Netherlands and budget
impact in Spain. The importance of information on costs
of smoking and smoking-attributable mortality showed
statistically significant variations by country, both receiv-
ing the highest score in Hungary and the lowest in
Spain, for costs of smoking and in Germany for
smoking-attributable mortality. The distribution of the
answers by the stakeholder category did not show a sta-
tistically significant variation in case of any HTA infor-
mation (Table 7). In most stakeholder categories, except
for professional service providers, cost-effectiveness was
considered to be the most important information.
The vast majority (81%) of the stakeholders proposed
other types of evidence in the open-ended questions
than those provided by the ROI tools, which they con-
sidered important in the decision-making process on the
implementation of tobacco control measures and smok-
ing cessation interventions. Their suggestions varied
greatly, the most frequent propositions were information
about absenteeism, days off work, more details about the
smoking cessation interventions (e.g. effectiveness, ac-
cessibility), cost, effect of smoking-related diseases on
quality of life, indirect costs, more detailed healthcare
utilization data popularity of a smoking cessation
programme among smokers, and results of target group
analysis.
Intention to use the ROI tool
Stakeholders from all sample countries expressed their
willingness to use a tool such as the Tobacco ROI tool
(Table 8). The Hungarian stakeholders were the most
committed to its use, while the Dutch and German in-
terviewees were least interested. Respondents from
Hungary and Spain wanted to use the tool basically as
soon as possible, while in the United Kingdom and
Germany they were more likely to introduce it in a year,
and the Dutch were uncertain about the timeframe of its
utilisation. The respondents almost unanimously expressed
that they would have liked to have more information about
the Tobacco ROI tool. The answers by the stakeholder
category were more homogeneous. Nevertheless, the pur-
chasers of services and pharma products were those who
most intended to use the tool, and the advocates of health
promotion were the least committed stakeholder group
(Table 9).
Discussion
The present study examined stakeholders’ views on the
use of the EQUIPT Tobacco ROI tool, a HTA-type deci-
sion support aid for tobacco control. We collected the
views of stakeholders with various roles across five coun-
tries by a semi-structured survey, and analysed the data,
including by stakeholder role and country, and reported
the initial findings.
A number of implications emerge from this unique
survey. Firstly, this study suggests that the stakeholders
consider it important that decisions on investments in
smoking cessation interventions should be supported by
HTA evidence. Further, stakeholders believe that all the
HTA information assessed (prevalence and cost of
smoking, quality of life, mortality due to smoking, effect-
iveness and cost-effectiveness of smoking cessation in-
terventions, and budget impact) is of great importance
and want the ROI tool to provide them with this infor-
mation. The majority of the stakeholders were familiar
with basic health economic concepts, but did not have
in-depth knowledge about the technical details. Overall,
the Tobacco ROI tool was received positively by stake-
holders; they were waiting for the final tool to be avail-
able for use, and most of the respondents would have
liked to use a tool such as the Tobacco ROI tool within
a year.
Secondly, when analysing the similarities and differ-
ences in views per stakeholder, the findings showed that
most stakeholders agreed with most questions which
were included in the questionnaire. They thought that
using a tool such as the EQUIPT Tobacco ROI tool in
decision-making was important. Nevertheless, the study
found differences between stakeholders: professional ser-
vice providers agreed the most with the statements that
smoking cessation interventions were effective and cost-
effective, while the purchasers of services thought mostly
that it was unacceptable that smoking cessation inter-
ventions were used without their efficacy being known.
Most of the stakeholders, except for professional service
providers, believed that the most important HTA infor-
mation was the cost-effectiveness of an intervention. In
accordance with our expectations, advocates of health
promotion intended to use a tool such as the ROI tool
the least, likely due to the burden of disease influencing
these stakeholders much more than the return on
investment.
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Table 6 Health technology assessment information deemed to be important by stakeholders by country (scale responses: 1 = strongly disagree; 7 = strongly agree)
Netherlands Hungary Germany Spain United Kingdom Total Kruskal–Wallis test
Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
Prevalence of smoking 28 5.89 (1.34) 16 6.38 (1.41) 17 5.82 (1.55) 18 5.78 (1.96) 14 5.64 (2.41) 93 5.90 (1.69) 0.38
Costs of smoking 28 6.29 (0.85) 16 7.00 (0.00) 17 6.53 (0.62) 18 6.28 (1.41) 14 6.71 (1.07) 93 6.52 (0.94) 0.002
Quality of life 28 5.79 (1.32) 16 6.13 (1.26) 17 5.41 (1.87) 18 6.06 (1.39) 14 5.86 (1.10) 93 5.84 (1.40) 0.63
Mortality due to smoking 28 6.11 (1.26) 16 6.75 (1.00) 17 5.88 (1.93) 18 6.33 (1.03) 14 6.64 (1.34) 93 6.30 (1.35) 0.010
Effectiveness of smoking cessation interventions (such as
quit and relapse rates)
28 6.39 (1.20) 16 6.50 (1.27) 17 6.18 (1.67) 18 6.39 (1.42) 14 6.71 (1.07) 93 6.42 (1.31) 0.35
Cost-effectiveness data comparing the cost of smoking
cessation interventions with its health and wider benefits
28 6.43 (0.88) 16 6.69 (0.48) 17 6.18 (1.02) 18 6.78 (0.43) 14 6.86 (0.36) 93 6.56 (0.74) 0.093
Budget impact reflecting financialoutcomes specifically at
organisational level






















Evidence generator Advocate of health
promotion
Total Kruskal–Wallis test
Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
Prevalence of smoking 29 5.66 (2.01) 7 6.71 (0.49) 18 6.33 (1.28) 25 5.84 (1.72) 14 5.57 (1.70) 93 5.90 (1.69) 0.43
Costs of smoking 29 6.55 (0.83) 7 6.71 (0.76) 18 6.61 (0.78) 25 6.36 (1.32) 14 6.50 (0.65) 93 6.52 (0.94) 0.81
Quality of life 29 6.17 (0.85) 7 6.14 (1.22) 18 5.61 (1.58) 25 5.64 (1.66) 14 5.64 (1.69) 93 5.84 (1.40) 0.76
Mortality due to smoking 29 6.59 (0.98) 7 6.57 (0.79) 18 6.33 (1.03) 25 6.20 (1.50) 14 5.71 (2.09) 93 6.30 (1.35) 0.68
Effectiveness of smoking cessation interventions
(such as quit and relapse rates)
29 6.59 (0.83) 7 6.71 (0.76) 18 6.56 (1.20) 25 6.12 (1.76) 14 6.29 (1.59) 93 6.42 (1.31) 0.76
Cost-effectiveness data comparing the cost of
smoking cessation interventions with its health
and wider benefits
29 6.66 (0.48) 7 6.86 (0.38) 18 6.33 (0.97) 25 6.52 (0.82) 14 6.57 (0.85) 93 6.56 (0.74) 0.65
Budget impact reflecting financial outcomes
specifically at organisational level
















Table 8 Stakeholders’ intention to use a tool such as the Tobacco ROI tool by country (scale responses: 1 = strongly disagree; 7 = strongly agree)
Netherlands Hungary Germany Spain United Kingdom Total Kruskal–Wallis test
Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
I have the intention to use a tool such as the Tobacco
ROI tool
28 4.64 (1.93) 16 6.88 (0.50) 17 4.47 (1.97) 17 6.29 (0.99) 14 5.57 (1.83) 92 5.45 (1.83) < 10–3
I have the intention to use a tool such as the Tobacco
ROI tool within the next month
28 3.18 (2.00) 16 6.31 (1.45) 17 3.00 (2.12) 16 6.38 (0.89) 14 4.14 (2.21) 91 4.41 (2.32) < 10–3
I have the intention to use a tool such as the Tobacco
ROI tool within the next 6 months
28 3.89 (2.13) 16 6.50 (1.10) 17 3.35 (2.23) 16 5.44 (1.75) 14 5.50 (1.65) 91 4.77 (2.16) < 10–3
I have the intention to use a tool such as the Tobacco
ROI tool within the next year
28 4.54 (2.13) 16 6.75 (0.58) 17 4.65 (1.94) 16 4.44 (1.97) 14 5.86 (1.66) 91 5.13 (1.98) < 10–3
I would like to have more information about the
Tobacco ROI tool
















Table 9 Stakeholders’ intention to use a tool such as the Tobacco ROI tool by stakeholder category (scale responses: 1 = strongly disagree; 7 = strongly agree)




Evidence generator Advocate of
health promotion
Total Kruskal–Wallis test
Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
I have the intention to use a tool such as the Tobacco ROI tool 29 5.59 (1.78) 7 5.71 (1.50) 18 5.44 (1.54) 24 5.42 (2.00) 14 5.07 (2.27) 92 5.45 (1.83) 0.97
I have the intention to use a tool such as the Tobacco ROI tool
within the next month
29 4.90 (2.29) 7 3.57 (2.57) 17 5.06 (1.92) 24 3.92 (2.28) 14 3.86 (2.63) 91 4.41 (2.32) 0.36
I have the intention to use a tool such as the Tobacco ROI tool
within the next 6 months
29 5.31 (2.12) 7 3.71 (2.06) 17 5.00 (2.06) 24 4.63 (2.06) 14 4.14 (2.48) 91 4.77 (2.16) 0.22
I have the intention to use a tool such as the Tobacco ROI tool
within the next year
29 5.24 (2.12) 7 4.86 (2.12) 17 5.41 (1.73) 24 5.08 (2.08) 14 4.79 (1.93) 91 5.13 (1.98) 0.77
I would like to have more information about the Tobacco ROI
tool
















Thirdly, when analysing the similarities and differ-
ences in views per country, the greatest level of
agreement existed for the statements that mortality
and societal costs of smoking were high and its epi-
demic was severe. However, differences between
countries were notable for most questions regarding
the relative importance of different elements of HTA
information.
The variation by stakeholder categories indicates that
different skillsets may exist amongst the stakeholders of
the included countries, and is in line with previous work
by the National Institute for Health and Care Excellence
(NICE) that found a range of people within England
could be involved in decision making about investment
in public health interventions [22]. This study corrobo-
rates that involving stakeholders early on in a research
project increases the likelihood of the research findings
being used in policymaking. Well thought-through
stakeholder engagement is therefore seen as a ‘pathway
to research impact’. Our results support the conclusion
of the NICE study, which reported that a conversation be-
tween decision makers and health economic researchers
should start at early stages of model development [22].
The differences found between the stakeholder categories
indicated that we need consider differentiation of variant
user levels (basic, moderate and advanced level) of a tool
such as the ROI tool in the development process and to
apply different outcome indicators by user level.
Generally, stakeholders’ answers showed larger vari-
ability by country than by stakeholder category. This is
interesting and highlights the importance of collecting
the views of stakeholders within each country as a step
in the process of developing a transferable tool. Without
these views, the usefulness of the Tobacco ROI tool be-
yond the country for which it was developed would be
unknown. Previous research [23–25] had discussed the
importance of context when considering transferability
of economic evidence and this factor will inform
ongoing work on the transferability of the EQUIPT
Tobacco ROI tool [13].
Once transferability within the sample countries has
been tested, we can consider further transferability of
the ROI tool to other countries beyond the sample
countries. This will enable countries with a smaller
tobacco control budget, but with perhaps a greater
need for tobacco control, to do so with more in-
formed techniques. This, in turn, should help reduce
tobacco use and thereby improve the health of their
citizens and reduce the burden of disease due to
smoking [4].
A limitation of our study is that the stakeholders
cannot be considered as a representative sample of all
stakeholders in the participating countries. Neverthe-
less, a range of major stakeholder categories were
represented from each participating country and the
final sample was the outcome of random responses
from our sampling frame. Therefore, we believe that
our results give a generalizable insight to the attitude
and expectations of stakeholders in relation to the
use of the Tobacco ROI tool. Another limitation of
this research is that the interviewing method was not
unified, most interviews were face-to-face, but in
some cases these were conducted by telephone or
Skype. In a face-to-face interview the uncertainty of
the responders can be managed much better and the
involvement in the survey can be more effective than
in a telephone or Skype interview. Nevertheless, we
think that the small number of telephone or Skype
interviews do not endanger the credibility of the
results.
Although HTA processes are based on internation-
ally recognised methods, significant disparities have
been observed to date in the recommendations made
by HTA agencies among different countries due to
the quality and type of evidence used [26]. Results of
these studies vary in context and topics. Regarding
tobacco control interventions, there has been no
evidence about the types of information deemed im-
portant for coverage decision. A large number of
attributes of interventions may be important in the
decision-making process (e.g. disease severity, budget
impact and costs per quality-adjusted life-year gained)
[27–29]. Koopmanschap et al. [9] found that the most
decisive decision criteria are severity of disease, costs
per quality-adjusted life-year gained, individual health
gain and the budget impact. Previous studies have
suggested that cost-effectiveness is not the single and
dominant concern [27, 28]. Our survey aimed to fill
in this gap with collecting the types of information
deemed to be important for decision to support the
development and transferability of the ROI tool.
An important advantage of this survey is that it
offers a unique dataset on the topic to fully analyse
several aspects of stakeholder engagement in research.
For example, there is a paucity of literature fully an-
swering questions as to what determines a stake-
holder’s likelihood of using economic evidence in
decision making, what the level of agreement is
within and between countries about what interven-
tions are relevant to their settings, and whether the
perceived ranking of what intervention is important
to stakeholder actually aligns with the ranking indi-
cated by published cost-effectiveness analyses. Most
transferability work in economic evaluation appears to
ignore this important pre-work involving stakeholder
engagement [30]. In this respect, future in-depth ana-
lyses based on this dataset investigating the above
questions would be highly welcome.
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Conclusions
This study shows that various types of stakeholders from
different countries consider HTA evidence important in
their decision-making process. They also consider them-
selves capable of interpreting the results from a return
on investment tool, and they are generally mostly moti-
vated to use a tool such as the ROI tool to aid their deci-
sion making. The survey findings serve as important
input to the development and country adaptation of the
ROI tool to ensure that the final product of the EQUIPT
project would reflect the needs and expectations of the
stakeholders.
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